Pulse Biosciences is a bioelectric-device developer with CellFX in a controlled commercial launch while concentrating much of its development effort on the nPulse platform, especially atrial fibrillation; Vybrance is an earlier-stage application in thyroid and soft-tissue ablation. This advances the thyroid program, but does not validate it yet. PRECISE-BTN is now fully enrolled at 100 patients, twice its original design. 〔0〕 The larger sample should make the eventual safety and effectiveness readout more informative, but the filing reports no clinical outcomes from the expanded cohort.
The direction was expected; the scale is the incremental news. Pulse had already identified completion of PRECISE-BTN enrollment as a near-term milestone, so this is not a major surprise. The meaningful detail is that enrollment reached 100 patients across three U.S. sites in roughly 12 months, rather than stopping at the original 50-patient plan. 〔1〕
The next value-bearing event is still the data readout. The first enrolled patient has completed the final 12-month follow-up, but the cohort remains in follow-up against endpoints including safety, nodule-volume reduction, symptom relief, hormone normalization, and quality of life. 〔2〕 Pulse says preliminary data will come at an upcoming medical society conference, with full data only after all patients complete 12-month follow-up. 〔3〕
Bottom line: This is a modestly constructive development for an already anticipated milestone: the larger study improves the evidence base, but the filing leaves the central clinical question—whether Vybrance works safely and effectively—unanswered until the data arrive.
Read the original 8-K on SEC EDGAR ↗